Lung Cancer
News
FDA approves osimertinib for first-line advanced EGFR-mutated NSCLC
Approval was based on a median PFS of 18.9 months for patients treated with osimertinib vs. 10.2 months for patients treated with standard-of-care...
Daily News Podcast
MDedge Daily News: Which diabetes drug boosts survival best?
And there’s new promise in early-stage lung cancer.
Conference Coverage
Nivolumab plus ipilimumab boosts PFS in advanced NSCLC with high tumor mutational burden
CHICAGO – In the first analysis from Checkmate 227, PFS was 7.2 months for the immunotherapy vs. 5.5 months for chemotherapy in patients with...
Conference Coverage
Nivolumab shows promise in early-stage resectable NSCLC
The majority of 20 patients with resectable NSCLC were alive and recurrence-free 1 year after surgery and nivolumab treatment.
Original Report
Analgesic management in radiation oncology for painful bone metastases
From the Journals
Bisphosphonate use linked with lower risk of lung cancer for never-smokers
Use of oral bisphosphonates was associated with a lower risk of developing lung cancer in postmenopausal women, but only those who were never...
Conference Coverage
Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC
ORLANDO – Checkpoint blockade associated with less combined direct and indirect toxicity, a systematic review and meta-analysis suggests.
From the Journals
Nivolumab helps some with advanced NSCLC reach 5-year mark
For 129 patients with previously treated advanced non-small cell lung cancer, the estimated 5-year overall survival rate was 16%.
Conference Coverage
CBC data can predict immunotherapy responses in NSCLC
ORLANDO – Readily available complete blood count data can help predict response to immunotherapy in patients with advanced NSCLC.
From the Journals
Lower socioeconomic status linked with poor NSCLC prognosis in those with pretreatment weight loss
Socioeconomic status, as measured by insurance status, was significantly prognostic among patients with NSCLC and pretreatment weight loss, but...
News
FDA wants data on role of flavored tobacco products in youth initiation
“Youth consistently report product flavoring as a leading reason for using tobacco products,” FDA Commissioner Gottlieb noted.